Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | Large Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) today announces its results for the third quarter 2021. Total revenue amounted to SEK 3,761 M, a 29 per cent growth at CER compared with the same period 2020. EBITA was SEK 1,166 M, resulting in an EBITA margin of 31 per cent.
July - September- Total revenue SEK 3,761 M (2,970), +27 per cent, +29 per cent at constant exchange rates (CER)
- Haematology revenue SEK 2,291 M (2,147), +9 per cent at CER of which Elocta® SEK 1,035 M (1,115), -6 per cent at CER, Alprolix® SEK 430 M (435), unchanged at CER, and Doptelet® SEK 400 M (145), +187 per cent at CER
- Immunology revenue SEK 1,144 M (619), +89 per cent at CER of which Kineret® SEK 516 M (463), +13 per cent at CER, Synagis® SEK 374 M (46), +769 per cent at CER, and Gamifant® SEK 255 M (110), +139 per cent at CER
- EBITA[1] SEK 1,166 M (933), EBITA margin[1] 31 per cent (31)
- Earnings per share (EPS) before dilution SEK 1.60 (0.94)
- Cash flow from operating activities SEK 257 M (381)
- Total revenue SEK 10,633 M (10,680), unchanged and +7 per cent at CER
- Haematology revenue SEK 6,294 M (6,578), +1 per cent at CER of which Elocta SEK 2,896 M (3,514), -14 per cent at CER, Alprolix SEK 1,281 M (1,286), +4 per cent at CER, and Doptelet SEK 810 M (396), +126 per cent at CER
- Immunology revenue SEK 3,450 M (3,133), +21 per cent at CER, of which Kineret SEK 1,608 M (1,493), +16 per cent at CER, Synagis SEK 1,286 M (1,294), +13 per cent at CER, and Gamifant SEK 556 M (346), +78 per cent at CER
- EBITA[1] SEK 3,572 M (4,124), EBITA margin[1] 34 per cent (39)
- EPS before dilution SEK 4.87 (5.92)
- Cash flow from operating activities SEK 3,349 M (4,209)
- Aspaveli® (pegcetacoplan) for PNH: positive CHMP opinion in the EU
- Revenue for the full year 2021 is expected to be in the range of SEK 14,500-15,000 M
- EBITA margin is expected to be in the range of 33-35 per cent of revenue
Guido Oelkers, CEO and President:
"We saw continued growth and pipeline progress in the third quarter of 2021, and it is satisfying to see that results are confirming our strategic direction. Overall, our two main business areas are in solid shape and they progressed as expected."
Financial Summary
[][][][][][][][][]
Q3 Q3 Jan Jan Full-year
-Sep -Sep
SEK M 2021 2020 Change 2021 2020 Change 2020
Total revenue 3,761 2,970 27% 10,633 10,680 0% 15,261
Gross profit 2,802 2,339 20% 8,165 8,318 -2% 12,036
Gross margin[1] 75% 79% 77% 78% 79%
EBITA[1] 1,166 933 25% 3,572 4,124 -13% 6,700
EBITA 1,166 933 25% 3,572 4,124 -13% 6,301
adjusted[1,2]
EBITA margin[1] 31% 31% 34% 39% 44%
EBITA margin 31% 31% 34% 39% 41%
adjusted[1,2]
Profit for the 473 278 70% 1,438 1,743 -18% 3,245
period
Earnings per 1.60 0.94 70% 4.87 5.92 -18% 11.01
share, before
dilution, SEK
Earnings per 1.60 0.94 70% 4.87 5.92 -18% 9.66
share, before
dilution, SEK
adjusted[1,2,3]
[1]Alternative
Performance
Measures
(APMs).
[2 ]EBITA in
2020 excluding
non-recurring
items; other
operating
income related
to
the reversal of
the CVR
liability of
SEK 399 M.
[3]EPS in full
-year 2020
excluding the
reversal of
the CVR
liability of
SEK 399
M.
Contacts
Thomas Kudsk Larsen
Head of Communication and Investor Relations
Maria Kruse
Director of Communication and Investor Relations
For details on how to contact the Sobi Investor Relations Team, please click here (https://www.sobi.com/en/investors). For Sobi Media contacts, click here (https://www.sobi.com/en/media).
Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology, and specialty indications. Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia, and Asia. In 2020, Sobi's revenues amounted to SEK 15.3 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.